PharmGKB summary

Autor: Teri E. Klein, Joan M. Hebert, Russ B. Altman, Jatinder K. Lamba, Erin G. Schuetz
Rok vydání: 2012
Předmět:
Zdroj: Pharmacogenetics and Genomics. 22:555-558
ISSN: 1744-6872
DOI: 10.1097/fpc.0b013e328351d47f
Popis: The aim of a PharmGKB VIP summary is to provide a simple overview of a gene with respect to drug effects. In some cases, there may be extensive evidence of variants that have known pharmacogenomic relevance, whereas in other cases, the summary may serve to highlight the gaps in knowledge where further study would aid the field. This summary points to the PharmGKB website to provide an interactive version that is linked to annotated publications and to related drugs, diseases, and pathways. The human CYP3A subfamily, CYP3A4, CYP3A5, CYP3A7, and CYP3A43, is one of the most versatile of the biotransformation systems that facilitate the elimination of drugs (37% of the 200 most frequently prescribed drugs in the US [1]). Together, CYP3A4 and CYP3A5 account for ~30% of hepatic cytochrome P450, and approximately half of the medications that are oxidatively metabolized by P450 are CYP3A substrates. Both CYP3A4 and CYP3A5 are expressed in the liver and intestine, with CYP3A5 being the predominant form expressed in extrahepatic tissues. The CYP3A5 cDNA sequence was first described independently by Aoyama et al. [2] and Schuetz et al. [3]. The CYP3A5 gene is located on chromosome 7q22.1 along with other CYP3A family members. The gene is on the minus chromosomal strand, consists of nine exons, and encodes a 502-amino-acid protein.
Databáze: OpenAIRE